PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma

Not yet recruiting

• Conditions: Multiple Myeloma
• Interventions: Other: Patient Interview

• Registration Number: NCT06322927
• Lead Sponsor: The Christie NHS Foundation Trust

Brief Summary

This is a qualitative (interview) study to explore the experiences of people receiving treatment for MM and to understand what matters most to them when making treatment decisions.

Detailed Description

People can receive many lines of treatment for multiple myeloma. We would like to understand more about the experiences of people being treated for multiple myeloma including what matters most to them when considering treatment options, how their experiences have differed with different treatments and if they have any treatment preferences. Patients at The Christie who have received five or more lines of treatment for Multiple Myeloma will be eligible to take part in this study. They will be asked to participate in an interview which should take approximately 30 minutes to an hour. During the interview they will be asked questions regarding their experiences and preference for treatment. Interviews will be conducted either in person or over the phone depending on patient preference. The interviews will be recorded by the research team using a Dictaphone and transcribed by an external transcription service called 1st Class Secretarial. The transcripts of all participant interviews will be reviewed by members of the research team and experiences will be identified and described.

Study Timeline

• Status Verified: 2024-03
• Study First Submitted: 2024-03-14
• Study First Submitted QC: 2024-03-14
• Last Update Submitted: 2024-03-14
• Study First Posted: 2024-03-21
• Last Update Posted: 2024-03-21
• Study Start: 2024-03-31
• Primary Completion: 2024-06-30
• Study Completion: 2024-09-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 15

Inclusion Criteria

1. Participants with confirmed MM (per standard disease specific diagnostic criteria)

2. Participants must have received ≥ 5 lines of treatment for MM and fit into one of the below treatment categories:

   1. Subset 1- Participants must have received an oral anti-cancer therapy and a bi-specific antibody treatment.
   2. Subset 2- Participants must have received an oral anti-cancer therapy and if they have not had a bi-specific antibody treatment, they must have received at least one IV therapy.

3. Aged 18 years of age or over

4. Able to provide informed consent

5. Able to communicate in English

Exclusion Criteria

1. Aged under 18
2. Unable to understand and communicate in the English language
3. Unable to provide written informed consent

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patient Interviews	Patient Interview	Participants will be asked to take part in a 30-60 minute interview to understand their treatment preferences. Members of the research team will conduct this either in the clinic or over the phone, as per patient preference.

Primary Outcome Measures

Name	Time	Method
Patient Experience and Preference	30-60 minutes	The interview will explore the experiences of people receiving treatment for multiple myeloma and understand what matters most to them when making treatment decisions.

Secondary Outcome Measures

Name	Time	Method
Treatment and Preference Differences	30-60 minutes	The interview will explore how experiences have differed across different lines of treatment and determine if people with multiple myeloma have any preferences for particular treatments.

Trial Locations

Locations (1)

The Christie NHS Foundation Trust; 🇬🇧 Manchester, Greater Manchester, United Kingdom